—
C+
C+ The full Closelooknet — membership. Open the C+ overview

Liquidia Technologies Inc (LQDA) — chart, structure and Closelooknet read

Pick a ticker to load its detail page.

Signals for this name

Every Closelooknet reading that exists for LQDA, from the same nightly bakes the boards use. Research diary readings, not advice.

Weather around the name 4 macro readings: Money Temperature, Factor regime, Sector × region …

The weather around this name

Macro readings that apply by membership — the regime, the factor tape, the sector cell, the funding backdrop.

  • Money Temperature Composite 56/100 · S&P 500 fund at 66, bullish alignedEight instruments scored on position, momentum, volume, volatility and fragility — the regime every name trades inside. Temperature lab → 2026-10-13
  • Factor regime Momentum leading — risk appetite buildingMomentum against low volatility (SPMO / SPLV): above its 50-day trend, 93th percentile of the window, +3.6% over 20 sessions. Factor regime → 2026-10-13
  • Sector × region Health care in US: +1.5% week · +1.5% month · +7.6% quarter · +19.4% yearThe Sector Engine cell this name lives in, from XLV.US; the 11 × 4 matrix shows where its sector is being bought and where it is being sold. Sector Engine → 2026-10-13
  • Sovereign pressure Index 0.04 · down 0.71 over 21 sessionsG7 long-end yields, 10s30s and the slope — the funding weather for every balance sheet on this site. Sovereign pressure → 2026-10-09
How it trades on rate days beta 0.37 to TLT · on the worst bond days it held up better than the market

How it trades on rate days

How LQDA has moved when long-dated Treasury yields rise — measured against TLT, the 20+ year Treasury fund.

  • Beta to long bonds, 1 year 0.37 — shows only a loose link to bond moves for every 1% move in TLT (20+ year Treasuries), Liquidia Technologies Inc moved 0.37% on average · correlation 0.04 · higher than 29% of US names
  • Beta, last 3 months 0.97 more rate-sensitive lately than over the year
  • On the 10 worst bond days +0.25% on average against −0.74% for the S&P 500 the 10 sessions of the past year in which TLT fell most, i.e. long yields rose most
  • Latest of those days +5.13% TLT −1.29% that day 2026-09-24

Daily total returns from the adjusted price series; a TLT down day is a day long yields rose. Beta = the average move of the name for a 1% move in TLT. Past sensitivity, not a forecast. An investment diary, not a recommendation.

Who it is priced against Drug Manufacturers - Specialty & Generic · US · 6 names with week and year-to-date

Peer group

Drug Manufacturers - Specialty & Generic · US

Names in the same industry from the Closelooknet universe; scored names rank on their Closelooknet score, the rest on trend state.

Compared against LQDA on the nightly bakes; the Peers tab ranks the cohort on the Closelooknet scores where it exists.

Company snapshot — Liquidia Technologies Inc

LQDA in five paragraphs: what it makes and sells, where it sits in the Closelooknet stack, who it is priced against, why we track it, what we watch. Research diary, not advice.

What it does
Liquidia Technologies develops and sells therapies for rare heart-and-lung diseases, mainly pulmonary hypertension. Its lead product, Yutrepia, is an inhaled dry-powder form of treprostinil, and it also sells Remodulin, an injected version of the same drug given through a pump. It is developing L606, a liposomal formulation of treprostinil now in late-stage trials, and holds a particle-engineering platform called PRINT that shapes drug particles with precise control. The company is based in Morrisville, North Carolina.
Where it sits in the stack
Liquidia carries no seat in our Closelooknet index. It sits within the Healthcare sector of our universe, in the specialty and generic drug-manufacturing sleeve, outside the AI build-out stack tracked elsewhere in the diary.
Who it is priced against
Closelooknet's peer group has not been built for this name. The comparison the market often draws is with United Therapeutics, another maker of treprostinil-based therapies for pulmonary hypertension.
Why Closelooknet tracks it
Liquidia holds no index seat and no score in our system; the diary has not yet built coverage on it.
What the diary watches
The diary watches whether uptake of the inhaled treprostinil product can hold ground against established pulmonary-hypertension therapies as it scales.

Liquidia Technologies Inc (LQDA) trades on US exchanges, classified under Healthcare.

The Closelooknet company score reads 45/100 composite (momentum 25, quality 67, valuation 36) across 7 modules — the full breakdown, chart structure and analog history load live above.

Written from the company’s public profile and Closelooknet’s own readings, 2026-09-17. Descriptive, refreshed with the registry; corrections welcome via the imprint. closelook.net is an investment research diary — market structure, index membership and scores are our own readings, not investment advice. Related: index compare · sector dispersion · scanner.

The Street on this name 1 analyst action on the wire · latest: price target by Raymond James, 2026-08-13

The Street on this name

Analyst actions and the latest print for LQDA from the Closelooknet wires — third-party opinions on the record, not our readings.

  • Price target Raymond James — target 106 from 68 Target raised to $106 from $68 (+35.1% to spot) 2026-08-13

1 action on the analyst wire since 2026-08-13: 1 target change. Analyst wire → · Earnings wire →

Dividends and capital return no distribution in twelve months

Dividends and capital return

What LQDA pays out and buys back — distributions read from the price series, money terms from the filings.

  • Distributions No cash distribution recorded in the price series over the last three years
  • Share count +9.3% in FY2025 29 m USD of stock-based compensation in the year

Per-share amounts are derived from the adjusted price series in the listing currency, so dates sit within days of the ex-date; filing figures come from the fundamentals feed for the last reported fiscal year. An investment diary, not a recommendation.

FAQ · from the current data · as of 2026-10-14

Quick answers

What is Liquidia Technologies Inc (LQDA)?

Liquidia Technologies Inc trades as LQDA on the US exchange (US) and is classified under Healthcare in the Closelooknet research universe, as of the registry build of 2026-10-14.

Is LQDA in a Closelooknet index?

Not currently — Liquidia Technologies Inc is tracked in the Closelooknet research universe but is not a constituent of a Closelooknet functional index as of 2026-10-14.

What is Liquidia Technologies Inc's Closelooknet composite score?

45 out of 100, with momentum 25, quality 67 and valuation 36 sub-scores, as of 2026-10-14. Scores are Closelooknet's own research readings, not ratings or investment advice.

Where does LQDA trade against its moving averages?

Mixed moving-average stack: Trades -58% vs the 50-day and -50.3% vs the 200-day average, 71.4% below the 52-week high and +22.2% off the 52-week low. Computed from daily closes. As of 2026-10-13 — a technical state from the nightly Closelooknet bake, not advice. The Technical tab carries the full row.

How does Liquidia Technologies Inc compare with its peers?

Against its peer group (Drug Manufacturers - Specialty & Generic · US), Liquidia Technologies Inc (LQDA) sits 71.4% below its 52-week high, 58.0% below its 50-day average; Lantheus Holdings Inc (LNTH) is 10.6% below, Kiniksa Pharmaceuticals Ltd (KNSA) is 5.3% below, GALDERMA GROUP AG (GALDY) is 13.2% below. Put any of them next to LQDA in the chart grid (2×1 or 2×2) and the page lays the companies side by side: performance, trend, valuation, margins and our money-flow reading.

How does Liquidia Technologies Inc trade when bond yields rise?

Over the past year Liquidia Technologies Inc had a beta of 0.37 to TLT, the long-dated Treasury fund — it shows only a loose link to bond moves, higher than 29% of US names. On the 10 sessions in which long bonds fell most it moved +0.25% on average, against −0.74% for the S&P 500. The "How it trades on rate days" block on this page carries the lines.

What does Liquidia Technologies Inc do?

Liquidia Technologies develops and sells therapies for rare heart-and-lung diseases, mainly pulmonary hypertension. Its lead product, Yutrepia, is an inhaled dry-powder form of treprostinil, and it also sells Remodulin, an injected version of the same drug given through a pump. It is developing L606, a liposomal formulation of treprostinil now in late-stage trials, and holds a particle-engineering platform called PRINT that shapes drug particles with precise control. Closelooknet's peer group has not been built for this name. The comparison the market often draws is with United Therapeutics, another maker of treprostinil-based therapies for pulmonary hypertension.

Where does Liquidia Technologies Inc sit in the AI build-out?

Liquidia carries no seat in our Closelooknet index. It sits within the Healthcare sector of our universe, in the specialty and generic drug-manufacturing sleeve, outside the AI build-out stack tracked elsewhere in the diary. Liquidia holds no index seat and no score in our system; the diary has not yet built coverage on it.

Does Liquidia Technologies Inc pay a dividend?

No cash distribution shows in Liquidia Technologies Inc’s price series over the last three years. The share count rose 9.3% over the fiscal year. The "Dividends and capital return" block on this page carries the lines.

What has Wall Street done on Liquidia Technologies Inc recently?

The most recent analyst action on Liquidia Technologies Inc on the Closelooknet wire is a price target by Raymond James on 2026-08-13 (target 106 from 68). 1 action on the analyst wire since 2026-08-13: 1 target change. Analyst actions are third-party opinions recorded by the wire, not Closelooknet readings. The “The Street on this name” block on this page lists the moves; the full feeds are the analyst wire and the earnings wire.

What does this page show?

A live price chart with SMA overlays and drawing tools for LQDA, performance metrics, index-membership context and the Closelooknet structure read — an investment research diary view, not investment advice.

Related in the Closelooknet universe

then Drug Manufacturers - Specialty & Generic, then Healthcare. Scored names rank on their Closelooknet score; names without one rank on trend state — above or below their 50- and 200-day averages — never on a score they do not carry.